yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Top Links You Must Click On

The Market for Breast Cancer Therapies in the BRIC Countries Will Grow at an Annual Rate of Eight Percent From $1.7 Billion to $2.5 Billion Between 2012 and 2017
The Launch of New Agents, an Increased Use of Targeted Therapies and a Rising Incident Population Will Contribute to BRIC Market Growth for the Treatment of Breast Cancer

BURLINGTON, Mass., Feb. 13, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market for breast cancer therapies in the BRIC countries (Brazil, Russia, India and China) will grow eight percent annually over the next five years, from $1.7 billion to $2.5 billion. The market's growth can be attributed to the launch of several premium priced agents, a gradual increase in the use of targeted therapies and a rise in the incident population.

According to the Emerging Markets report entitled Breast Cancer in the BRIC Markets, the Brazilian breast cancer market is currently the largest of the BRIC and accounts for 50 percent of the total market share for breast cancer therapies. However, while these market shares will remain consistent, the Chinese market is anticipated to develop the most through 2017.

"Among the BRIC nations, China will experience the greatest growth over the forecast period," said Decision Resources Analyst Andreia Ribeiro, Ph.D. "This will primarily be driven by the rising number of incident cases and changes in medical practice towards more personalized treatments, especially trastuzumab and GlaxoSmithKline's soon-to-launch Tykerb."

The report findings reveal that HER2-targeting agent trastuzumab (Roche's Herceptin) is the brand leader in sales across all the BRIC markets in 2012, and in 2017, it maintains its premium position despite loss of market share. Overall, the use of targeted therapies is expected to increase in the BRIC, garnering sales of $615 million to $1.16 billion between 2012 and 2017. Increased and improved patient access to these costlier agents – aided by the entry of a biosimilar version of trastuzumab – will be major drivers of sales in these markets.

Growth of the breast cancer markets in the BRIC will also be determined by the launch of several new therapies over the forecast period, which will be comprised of novel and modified HER2-targeting agents (Roche's Perjeta and Roche's antibody-drug conjugate, trastuzumab-DM1), novel chemotherapeutic agents (Eisai's Halaven and Bristol-Myers Squibb's Ixempra) and a novel targeted therapy (Novartis's Afinitor). Together, these emerging therapies will contribute approximately nine percent to overall breast cancer sales in the BRIC markets in 2017.

The new report features extensive primary research with BRIC oncologists as well as a market outlook for key drugs through 2017 and breast cancer epidemiology through 2021.

About Emerging Markets Reports
Decision Resources is the first and only company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources

Decision Resources Group

Allison Thrower

Liz Marshall



SOURCE Decision Resources

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
Ten short years ago, Apache Hadoop was just a small project deployed on a few machines at Yahoo and within a few years, it had truly become the backbone of Yahoo’s data infrastructure. Additionally, the current Apache Hadoop market is forecasted to surpass $16 billion by 2020. This mi...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the...
The Open Connectivity Foundation (OCF), sponsor of the IoTivity open source project, and AllSeen Alliance, which provides the AllJoyn® open source IoT framework, today announced that the two organizations’ boards have approved a merger under the OCF name and bylaws. This merger will ad...
Virgil consists of an open-source encryption library, which implements Cryptographic Message Syntax (CMS) and Elliptic Curve Integrated Encryption Scheme (ECIES) (including RSA schema), a Key Management API, and a cloud-based Key Management Service (Virgil Keys). The Virgil Keys Servic...
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the n...
Apache Hadoop is a key technology for gaining business insights from your Big Data, but the penetration into enterprises is shockingly low. In fact, Apache Hadoop and Big Data proponents recognize that this technology has not yet achieved its game-changing business potential. In his ...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers